Workflow
AngioDynamics(ANGO) - 2024 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported revenue of 66millionforQ3FY24,representingan866 million for Q3 FY24, representing an 8% year-over-year growth, with med tech segment growth of nearly 13% and med device segment growth of 5% [10][20] - Adjusted net loss for Q3 FY24 was 6.5 million, or adjusted loss per share of 0.16,comparedtoanadjustednetlossof0.16, compared to an adjusted net loss of 5.4 million or adjusted loss per share of 0.14inthesamequarterlastyear[26]GAAPnetlossforQ3FY24was0.14 in the same quarter last year [26] - GAAP net loss for Q3 FY24 was 190.4 million, including a goodwill impairment charge of 159.5million[27]BusinessLineDataandKeyMetricsChangesMedtechrevenuewas159.5 million [27] Business Line Data and Key Metrics Changes - Med tech revenue was 25.7 million, a 12.6% year-over-year increase, while med device revenue was 40.3million,growing5.240.3 million, growing 5.2% compared to Q3 FY23 [20] - Auryon platform contributed 11.8 million in revenue during Q3, growing 14.7% year-over-year [21] - NanoKnife disposable revenue increased 19.8% year-over-year, with capital sales growing 230.9% [22] Market Data and Key Metrics Changes - International business grew approximately 21% year-over-year, with med tech growing 53% and med device growing 7% [16] - The company expects to initiate a limited launch of AlphaVac for pulmonary embolism treatment by the end of Q4 FY24, with a full launch scheduled for Q1 FY25 [12][13] Company Strategy and Development Direction - The company is focused on optimizing its portfolio, having divested its PICC and midline product portfolios for up to 45million,with45 million, with 30 million received in Q3 [17] - The transition to a fully outsourced manufacturing model is underway, expected to generate approximately 15millioninannualizedsavingsstartinginFY26[18][24]Thecompanyaimstodrivegrowthfromkeymedtechplatformswhileexpandingmarginsandmovingtowardsprofitability[9]ManagementsCommentsonOperatingEnvironmentandFutureOutlookManagementexpressedconfidenceinthegrowthstrategy,highlightingtheFDAclearanceforAlphaVacasasignificantmilestone[12]ThecompanyanticipatesFY24revenueintherangeof15 million in annualized savings starting in FY26 [18][24] - The company aims to drive growth from key med tech platforms while expanding margins and moving towards profitability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting the FDA clearance for AlphaVac as a significant milestone [12] - The company anticipates FY24 revenue in the range of 270 million to 275million,reflectingtheimpactofrecentdivestitures[32]Managementnotedthattherearenosignificantmarketchangesaffectingguidance,maintainingaconsistentoutlookdespiteoperationaltransitions[42]OtherImportantInformationThecompanyhaszerodebtcomparedto275 million, reflecting the impact of recent divestitures [32] - Management noted that there are no significant market changes affecting guidance, maintaining a consistent outlook despite operational transitions [42] Other Important Information - The company has zero debt compared to 50 million a year ago, significantly strengthening its balance sheet [28][30] - A settlement agreement with BD Bard was reached, resolving over a decade of IP litigation, providing clarity and allowing the company to focus on growth [31] Q&A Session Summary Question: When will data from the APEX trial be available? - Management indicated that data will be released at upcoming trade shows and through publications from principal investigators [36] Question: What are the rollout plans for AlphaVac in PE? - The company has prepared its sales force and will conduct a limited market release followed by a larger launch [48] Question: Will there be any changes in guidance due to recent divestitures? - Management confirmed that guidance remains consistent, reflecting the divestiture's impact without significant market changes [42] Question: What is the pricing strategy for AlphaVac? - The expected price for AlphaVac is around $9,000 [60] Question: How is the NanoKnife performing and when will PRESERVE data be available? - The NanoKnife is seeing strong growth, particularly in prostate treatments, with data from the PRESERVE study expected to be published following the 12-month follow-up [62]